Eli Lilly and Company: Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing ...
Le Lézard

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Johnson & Johnson today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in ...
Clinical Trials Arena on MSN

Zenas’ bifunctional mAb scores at Phase II in relapsing MS

During the Phase II MoonStone study (NCT06564311), the bifunctional monoclonal antibody (mAb) met its primary endpoint, ...
clinicaltrialsarena

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win

The subcutaneous (SC) drug’s safety and tolerability profile ... with the most common events being headache, reactions at the injection site and diarrhoea. If gefurulimab were to gain approval in gMG, ...

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Biogen Inc. ( BIIB) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to ...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy ...

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call October 30, 2025 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...